Pfizer Inc
PFE
Company Profile
Business description
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Contact
66 Hudson Boulevard East
New YorkNY10001-2192
USAT: +1 212 733-2323
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
Long term outlook intact for wide moat income share
Acquisition gains balance traffic headwinds.
stocks
ASX rare earths play looks to expand production
The largest rare-earth producer outside of China acquires competitor to increase production.
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Draft IPO filing shows a company growing faster than its annual results can capture.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,898.30 | 5.20 | -0.06% |
| CAC 40 | 7,865.07 | 30.97 | 0.40% |
| DAX 40 | 25,449.19 | 194.98 | 0.77% |
| Dow JONES (US) | 51,521.28 | 253.38 | 0.49% |
| FTSE 100 | 10,541.69 | 43.75 | 0.42% |
| HKSE | 24,280.56 | 240.22 | 1.00% |
| NASDAQ | 27,599.79 | 122.48 | 0.45% |
| Nikkei 225 | 70,683.98 | 737.12 | 1.05% |
| NZX 50 Index | 13,707.87 | 7.75 | 0.06% |
| S&P 500 | 7,818.93 | 44.98 | 0.58% |
| S&P/ASX 200 | 8,730.60 | 5.10 | -0.06% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |